This site is intended for health professionals only

European committee backs constipation drug


An advisory committee has recommended that a constipation drug created by Progenics Pharmaceuticals Inc is approved for use in prefilled syringes.

The Committee for Medicinal Products for Human Use – part of the European Medicines Agency – recommended that Relistor gets the green light for use.

The European Commission will consider this when deciding whether the drug – which uses opioid painkillers to treat constipation – is approved for use, while the US Food and Drug Administration (FDA) will also rule on it.

Article continues below this sponsored advert
Cogora InRead Image
Join us at a one-day virtual cardiology event that will allow you to explore the latest advances in cardiovascular care. With the help of an advisory board of cardiology specialists we have put together an agenda tailored to multi-disciplinary teams - each talk is presented by an expert, or panel, who will share knowledge and case studies of relevance

Progenics expects pre-filled syringe commercial launches to take place in the United States and European Union during the second quarter of 2011, pending approval.

Progenics Pharmaceuticals, Inc, of Tarrytown, New York, is a biopharmaceutical firm focusing on the development and commercialisation of innovative therapeutic products to treat the medical needs of patients who have life-threatening diseases and debilitating conditions.

Copyright © Press Association 2010

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine